# Q EVIDENCE SYNOPSIS

**Title:** Benefits and Harms of Sunscreens to Decrease Ultraviolet Exposure from Sunlight

Date completed: May 28, 2015

Authors: Steven Lascher, DVM, PhD, MPH and David R. Goldmann, MD

Clinical question: What are the benefits and harms of sunscreens to decrease ultraviolet (UV) exposure from sunlight?

#### Author recommendations:

To prevent UV irradiation of the skin when exposed to sunlight, clinicians should recommend the use of broad-spectrum sunscreen with a minimum sun protection factor (SPF) rating of 15, applied in a dose of at least 2 mg/cm² every 2 hours during sun exposure.

Additional safeguards include limiting ultraviolet A (UVA) and ultraviolet B (UVB) radiation from 10 a.m. to 2 p.m. and wearing hats and sun-protective clothing.

#### Evidence and recommendations:

Quality of Evidence <sup>a</sup>	Strength of Recommendations <sup>b</sup>	Conclusion
Low	Strong	The potential preventive benefits of SPF 15 or higher sunscreen strongly outweigh the risks

<sup>\*</sup>Quality of evidence scale (Grading of Recommendations Assessment, Development and Evaluation [GRADE]): high, moderate, low, and very low.

Strength of recommendations scale (GRADE): strong, weak, or no recommendation. For more information on the GRADE rating system, see http://www.gradeworkinggroup.org/index.htm.

## PICO:

Population	Healthy persons exposed to sunlight Time of day Duration and frequency of exposure
Intervention	Topical physical sunscreens (e.g., titanium dioxide, zinc oxide) Topical chemical sunscreens (e.g., para-aminobenzoic acid, avobenzone) Clothing with or without SPF With or without other sun avoidance and protective measures Dose, frequency, duration
Comparator	No sunscreen; other avoidance or protective measures only; sunscreen with beta-carotene; placebo Discretionary sunscreen use, active comparators
Primary outcome(s)	Long-term clinical effects of sunburn: solar keratosis counts, nevi counts  Development of cancerous lesions; precancerous lesions; cancer rates: basal cell carcinoma, squamous cell carcinoma, cutaneous malignant melanoma, actinic neoplasia (keratosis)  Safety outcomes: all harms

What are the parameters of our evidence search? Refer to the following tables (Tables 1 and 2)

TABLE 1 Outcome: Sunscr	een for Prevention of Solar	TABLE 1 Outcome: Sunscreen for Prevention of Solar (Actinic) Keratosis: Standardized Mean Difference	lized Mean Difference <sup>a</sup>		
Study (Year) Design Study Duration	Comparator	Intervention	Standardized Mean Difference Estimate(95% Cl) N	Quality of Evidence (GRADE)	Comment
Darlington (2003) RCT 1992-1994 Sunscreen sites only	Discretionary use of sunscreen	SPF 16 as directed	-0.13 (-0.25, -0.02) 1116	High risk	Solar keratosis counts were somewhat lower compared with 1992 in the intervention group
Darlington (2003) <sup>†</sup> RCT 1992-1994 Full body	Discretionary use of sunscreen	SPF 16 as directed	-0.14 (-0.26, -0.03) 1116	High risk	Solar keratosis counts were somewhat lower compared with 1992 in the intervention group
Darlington (2003) <sup>1</sup> RCT 1994-1996 Sunscreen sites	Discretionary use of sunscreen	SPF 16 as directed	-0.03 (-0.15, 0.09) 1116	High risk	No statistically significant difference in solar keratosis counts during the second 2-year follow-up period
Darlington (2003) <sup>†</sup> RCT 1994-1996 Full body	Discretionary use of sunscreen	SPF 16 as directed	-0.03 (-0.15, 0.09) 1116	High risk	No statistically significant difference in solar keratosis counts during the second 2-year follow-up period
Thompson (1993) <sup>2</sup> RCT 1 year	Placebo (base cream minus active ingredient)	SPF 17 cream on head, neck, forearms, and hands	-4.32 (-4.66, -3.97) 588	High risk	The sunscreen group had a reduction in lesions, while the comparator group's lesions increased in number 27% dropout rate
Naylor (1995) <sup>3</sup> RCT 2-year follow-up	Placebo (base cream minus active ingredient)	SPF 29 applied at least daily	-0.55 (-1.11, 0.02)* -0.77* (-1.36, -0.17)	High risk	Statistically significant difference in lesions in the intervention group, as reported and calculated using Glass's Delta 1 Small sample size
Statistically significant findings are in hold font	in hold font				

<sup>&</sup>quot;Statistically significant findings are in bold font.
"Cohen's of calculated with unequal variances.
"Others of Calculated with unequal variances.
C), Confidence interval; 6RADE, Grading of Recommendations Assessment, Development and Evaluation, RCT, randomized controlled trial; SPF, sun protection factor.

TABLE 2 Outcome: Sunscreen for Prevention of Skin Cancers	vention of Skin Cancers					
Study Description and Outcome	ILLUSTRATIVE COMPARATIVE RISKS (95% CI)	ATIVE RISKS (95% CI)	Rate Ratio (95% CI)	Number of	Quality of	Comment
rears	Assumed Risk Rate of Outcome in Control Groups	Corresponding Risk with Sunscreen Intervention	NNIP (95% CI)	Participants	(GRADE)	
Green (1999) <sup>4</sup> RCT, 4-year follow-up	25.09/1000 individuals	25.88/1000 individuals	1.03 (0.73, 1.46)	1383	High risk	Control group used discretionary
SPF 16 as directed			NA			sunscreen
Green (1999) <sup>4</sup> RCT	9.96/1000 individuals	8.76/1000 individuals	0.88 (0.50, 1.56)	1383	High risk	ı
Squamous cell carcinoma						
SPF 16 as directed			NA			
1992-1996						
Van der Pols (2006) <sup>5</sup>	12.70/1000 individuals	12.96/1000 individuals	1.02 (0.78, 1.35)	1484	High risk	1
RCT, 8-year follow-up						
1993-2004			NA			
Basal cell carcinoma						
Van der Pols (2006) <sup>5</sup>	8.11/1000 individuals	5.45/1000 individuals	0.65 (0.45, 0.94)	1484	ı	ı
RCT, 8-year follow-up						
1993-2004			$-14^{a}$ (6, $-4$ )			
Squamous cell carcinoma						
Green (2011) <sup>6</sup> RCT, 15-year follow-up	13.6/1000 individuals	3.7/1000 individuals	0.27 (0.08, 0.97)	1621	High risk	ı
Invasive melanoma			$-4^{a}$ (-42, -2)			

(e.g., sunscreen use results in a lower invasive melanoma rate in the intervention group).
C), Confidence interval; 674DE, Grading of Recommendations Assessment, Development and Evaluation; MA, not applicable; MMD, absolute value of 1/absolute risk reduction when the intervention is preventive; RCT, randomized controlled trial; SPF, sun protection factor. "ANVIP is the absolute value of 1/absolute risk reduction when the intervention is preventive. In all cases, the control group rate is greater than the intervention group rate, otherwise yielding a negative number

**Guidelines:** Ultraviolet Radiation and the INTERSUN Programme. World Health Organization<sup>7</sup> (AGREE II score: Not scored) No strength of recommendations or quality of evidence ratings.

- Use sunscreen: Apply a broad-spectrum sunscreen of SPF 15+ liberally, and reapply every 2 hours or after working, swimming, playing, or exercising outdoors. Sunscreen should never be used to prolong the duration of sun exposure.
- Limit time in the midday sun: The sun's UV rays are strongest between 10 a.m. and 4 p.m. To the extent possible, limit exposure to the sun during these hours.
- Watch for the UV Index: This important resource helps you plan your outdoor
  activities in ways that prevent overexposure to the sun's rays. While you should always
  take precautions against overexposure, take special care to adopt sun safety practices when
  the UV Index predicts exposure levels of moderate or above.
- Use shade wisely: Seek shade when UV rays are the most intense, but keep in mind
  that shade structures such as trees, umbrellas, or canopies do not offer complete sun
  protection. Remember the shadow rule: "Watch your shadow. Short shadow, seek
  shade!"
- Wear protective clothing: A hat with a wide brim offers good sun protection for your
  eyes, ears, face, and the back of your neck. Sunglasses that provide 99-100% UVA and
  UVB protection will greatly reduce eye damage from sun exposure. Tightly woven,
  loose-fitting clothes will provide additional protection from the sun.

Position Statement on Broad Spectrum Protection of Sunscreen Products. The American Academy of Dermatology. Revised 2009.8 (AGREE II score: Not scored) No strength of recommendations or quality of evidence ratings.

- Use a broad-spectrum (UVA and UVB protection) sunscreen with SPF 30 or higher that
  meets the UVA protection criteria defined below.
  - Sunscreen UVB protection, as reflected by SPF, is an important initial consideration for sunscreen potency. UVA protection is an equally important consideration for sunscreen potency.
  - The UVA protection factor of a sunscreen should reflect at least a 10-fold increase in the UVA dose needed to induce a purified protein derivative (PPD) response, and it must be accompanied by a critical wavelength of 370-400 nm.
  - An increase in sunscreen SPF must be accompanied by a proportional increase in the UVA protection factor as measured by the PPD method. The ratio of UVA:UVB protection factors should be 1:3 at a minimum (e.g., an SPF 30 sunscreen will have at least a UVA protection factor of 10).
  - Only sunscreens that demonstrate both UVA and UVB protection may claim broadspectrum coverage.
- · Additional American Academy of Dermatology resources.

Behavioral Counseling to Prevent Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement; 2012. Moyer VA, on behalf of the U.S. Preventive Services Task Force (AGREE II Score: Score unavailable). Grade B recommendation: The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.

- Provide counseling about minimizing exposure to UV radiation to reduce the risk of skin cancer (for ages 10-24). (Grade B) For adults older than 24 years, there is insufficient evidence.
- Individuals with a fair skin type are at greatly increased risk for skin cancer.
- Behavioral change interventions are aimed at reducing UV radiation exposure. Sunprotective behaviors include the use of a broad-spectrum sunscreen with an SPF of ≥15, wearing hats or other shade-protective clothing, avoiding the outdoors during midday hours (10 a.m. to 3 p.m.), and avoiding the use of indoor tanning.

Sunscreen: The ABCs of Sun Protection. FDA; 2015. 10 (AGREE II Score: Not scored) No strength of recommendations or quality of evidence ratings.

 Use broad-spectrum sunscreens with SPF values of 15 or higher regularly and as directed.

- Reapply sunscreen at least every 2 hours; more often if you're sweating or jumping in and out of the water.
- Limit time in the sun, especially between the hours of 10 a.m. and 2 p.m., when the sun's rays are most intense.
- Wear clothing to cover skin exposed to the sun; for example, long-sleeved shirts, pants, sunglasses, and broad-brimmed hats.

**Author commentary:** We searched the literature on prevention of sunburn with sunscreen use. Though we found no studies that focused on acute sunburn, we included studies with precursor and intermediate clinical conditions that have been identified as skin cancer risk factors. Three of the included studies are based on the original work done in Queensland, Australia. He Because of the setting, these results may not be generalizable to more temperate climates. Nevertheless, the studies show a statistically significant protective effect of sunscreen in decreasing the development of solar keratosis, squamous cell carcinoma, and melanoma over the long term. For all outcomes and over a 10-year follow-up period, the results show no protective effects for beta carotene (30 mg/day). There are no reported harms associated with sunscreen use, although the effect of conscientious sunscreen use on vitamin D levels remains controversial, as the research findings are conflicting. Overall, the evidence is rated low quality because of its high risk of bias and inconsistency across study results.

Despite its low quality, the evidence from the included RCTs supports the use of an effective broad-spectrum sunscreen with an SPF level of 15 or higher to cover sun-exposed skin, as the longer-term benefits may be far greater than the potential harms. There remain diverse opinions about whether higher SPF ratings provide greater risk reduction. Higher-rated sunscreens are more effective in blocking UV rays, and FDA regulations require a 2 mg/cm² application density for SPF testing. One argument is that higher SPF ratings (e.g., greater than 50) provide a greater margin of safety, as sunscreen is typically applied at 20-50% of the SPF-rated amount. <sup>12</sup>

Our recommendations are consistent with current clinical practice guidelines.

**Update alerts:** Important new citations relevant to this topic are added here as they become available.

Glossary: AGREE II, Appraisal of Guidelines for Research and Evaluation; CI, confidence interval; FDA, US Food and Drug Administration; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NA, not applicable; NNT, number needed to treat; NNTp, absolute value of 1/absolute risk reduction when the intervention is preventive; PPD, purified protein derivative; RCT, randomized controlled trial; SPF, sun protection factor; UV, ultraviolet; UVA, ultraviolet A; UVB, ultraviolet B.

### **REFERENCES**

- Darlington, S., Williams, G., Neale, R., et al., 2003. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch. Derm. 139 (4), 451–455.
- Thompson, S.C., Jolley, D., Marks, R., 1993. Reduction of solar keratoses by regular sunscreen use. N. Engl. J. Med. 329 (16), 1147–1151.
- Naylor, M.F., Boyd, A., Smith, D.W., et al., 1995. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Derm. 131 (2), 170–175.
- Green, A., Williams, G., Neale, R., et al., 1999. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354 (9180), 723–729.
- van der Pols, J.C., Williams, G.M., Pandeya, N., et al., 2006. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol. Biomarkers Prev. 15 (12), 2546–2548.

- Green, A.C., Williams, G.M., Logan, V., et al., 2011. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J. Clin. Oncol. 29 (3), 257–263.
- World Health Organization. Ultraviolet radiation and the INTERSUN Programme: Sun protection. <a href="http://www.who.int/uv/sun\_protection/en/">http://www.who.int/uv/sun\_protection/en/</a>> (accessed May 27, 2015).
- American Academy of Dermatology. Position statement on broad spectrum protection of sunscreen products. <a href="https://www.aad.org/forms/policies/uploads/ps/ps-broad-spectrum%20protection%20of%20sunscreen%20products.pdf">https://www.aad.org/forms/policies/uploads/ps/ps-broad-spectrum%20protection%20of%20sunscreen%20products.pdf</a>. Amended November 14, 2009 (accessed May 28, 2015).
- Moyer, V.A., Force USPST, 2012. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157 (1), 59–65.
- US Food and Drug Administration. Sunscreen: The ABCs of sun protection. <a href="http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/ucm239463.htm#bottom">http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/ucm239463.htm#bottom</a>. Updated January 6, 2015 (accessed May 28, 2015).
- Linos, E., Keiser, E., Kanzler, M., et al., 2012. Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. Cancer Causes Control 23 (1), 133-140.
- Russak, J.E., Chen, T., Appa, Y., et al., 2010. A comparison of sunburn protection of high-sun protection factor (SPF) sunscreens: SPF 85 sunscreen is significantly more protective than SPF 50.
   J. Am. Acad. Dermatol. 62 (2), 348–349.

**Recommended citation:** Lascher S, Goldmann DR; Elsevier Evidence-Based Medicine Center: Evidence Review: Benefits and Harms of Sunscreens to Decrease Ultraviolet Exposure from Sunlight. Publication date: May 28, 2015. Access date: May 29, 2015.